We are thrilled to announce that Oxford Immune Algorithmics signed last week a collaboration and commercial agreement with the National Health Service in the UK to serve and continue co-developing Algocyte® in Addenbrooke's Hospital at the Cambridge University Hospitals NHS Foundation Trust, one of the most important hospitals in the UK.
Algocyte® will be deployed at the Department of Paediatric Haematology, Oncology and Palliative Care to help paediatric cancer patients to get supportive monitoring while preventing them to visit the hospital where they are exposed to greater risk of infection due to COVID-19.
We want to thank partners, collaborators and investors that made this possible believing in us and supporting our project to help clinicians and these vulnerable patients.
We are happy to announce that Oxford Immune Algorithmics has been nominated to the OBN awards for the Best Start-up Medtech in the UK. The awards celebrate outstanding achievement throughout the life sciences industry.
OBN is the not-for-profit organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Their 400-plus Member companies are located across the Golden Triangle (Oxford, London and Cambridge) and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland.
The nomination already feels like winning and we are very grateful to OBN for this prestigious nomination.